This research updates expert approaches to preclinical studies and evaluates regulatory requirements in radiopharmaceutical development.
Key Points
Preclinical studies of radiopharmaceuticals must adhere to both EAEU and European Union regulatory guidelines, emphasizing similar fundamental approaches.
Assessing pharmacokinetic and pharmacodynamic parameters, alongside toxicological aspects, is essential for the development of radiopharmaceuticals.
Specific preclinical studies include evaluating binding specificity, selecting radionuclides, and appropriate in vivo models for effective research outcomes.
The study highlights the importance of aligning scientific recommendations with regulatory frameworks for successful radiopharmaceutical development.